Open access journal of the Ferrata-Storti Foundation, a non-profit organization
Comments

Targeting leukemia stem cells in unfit acute myeloid leukemia with a CD70-directed third agent: promise and caveats from the ELEVATE trial. Comment on: “Cusatuzumab combined with venetoclax with or without azacitidine in unfit patients with newly diagnosed acute myeloid leukemia: phase Ib ELEVATE study”

Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, Henan
Department of Hematology, The Affiliated Cancer Hospital of Zhengzhou University and Henan Cancer Hospital, Zhengzhou 450008, Henan
Haematologica Early view Oct 1, 2026 https://doi.org/10.3324/haematol.2026.302003

Abstract

Not available.

Figures & Tables

Article Information

Early view : Comments
 
DOI
https://doi.org/10.3324/haematol.2026.302003
 
Published
2026-10-01
Published By
Ferrata Storti Foundation, Pavia, Italy
Print ISSN
0390-6078
Online ISSN
1592-8721
 
Copyright & Usage
Copyright (c) 2026 Ferrata Storti Foundation
Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

Article Usage

Online Views
170
PDF Downloads
124
No Data
PlumX
Navigate
For Authors
For Reviewers
For Advertisers
Education
Privacy
More
Copyright © 2026 by the Ferrata Storti Foundation | Web design ￫ | Development ￫
ISSN 0390-6078 print | ISSN 1592-8721 online